Roche Reports Submission of sBLA to the US FDA for Tecentriq (atezolizumab) + Avastin (bevacizumab) to Treat Unresectable Hepatocellular Carcinoma

Shots:

• The sBLA is based on P-III IMbrave150 study involve assessing of Tecentriq (1200mg, IV) + Avastin (IV, 15 mg/kg) vs Sorafenib (PO, 400mg, bid) in 501 patients in a ratio 2:1 with unresectable HCC prior not treated with systemic therapies
• The P-III IMbrave150 study results: 42% reduction in risk of death; 41% reduction in risk of disease worsening or death; safety profile is consistent with the individual therapies, presented at ESMO201
• Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptor. The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq ability to restore anti-cancer immunity, by inhibiting VEGF related immunosuppression

Click here ­to­ read full press release/ article | Ref: Roche | Image: Behance